Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in IGT, T2DM, and Healthy Subjects
NCT01248364Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2010
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of empagliflozin in type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), sponsored by Boehringer Ingelheim. Started Nov 2010; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT01248364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01248364.